Key statistics
On Friday, Elanco Animal Health Inc (5EA:FRA) closed at 13.36, -22.00% below its 52-week high of 17.12, set on Jun 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.36 |
---|---|
High | 13.36 |
Low | 13.36 |
Bid | 13.07 |
Offer | 13.17 |
Previous close | 13.37 |
Average volume | 1.78k |
---|---|
Shares outstanding | 494.33m |
Free float | 491.04m |
P/E (TTM) | 34.43 |
Market cap | 6.96bn USD |
EPS (TTM) | 0.4087 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:19 GMT.
More ▼
Press releases
- Elanco Animal Health Reports Third Quarter 2024 Results
- Elanco Confirms Date and Conference Call for Third Quarter 2024 Financial Results Announcement
- Elanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose
- Elanco Announces FDA Approval and Launch of Zenrelia™ (ilunocitinib tablets), Offering An Effective, Safe Solution in Canine Dermatology
- Elanco Provides Update on Contract Manufacturing Partner
- Elanco to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
- Elanco Announces Credelio Quattro Moves to Final FDA Administrative Review
- Credelio® (lotilaner) Kills Ticks 2x as Fast as Simparica TRIO® (sarolaner, moxidectin and pyrantel) and NexGard® (afoxolaner)
More ▼